Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following phacoemulsification surgery

Evaluation of the Efficacy, safety, and tolerability of Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following uneventful phacoemulsification surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202207762785564

Enrollment

800

Registered

2022-07-11

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Topical Prednisolone acetate eyedrops

Topical Difluprednate eyedrops

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age more than 50 years 2. Patients diagnosed to have cataract, LOCS III cataract classification: NO = 2 and NC = 2)

Exclusion criteria

Exclusion criteria: 1. Known sensitivity to any of the ingredients in this study medication 2. History of glaucoma or ocular hypertension in the study eye 3. Previous history of steroid-induced increase of intraocular pressure (IOP) 4. Previous ocular surgery 5. history of uveitis 6. Intraoperative complications as posterior capsule rupture 7. Diabetic patients, Pregnancy, Autoimmune patients, and Single eyed patient.

Design outcomes

Primary

Measure	Time frame
Efficacy, safety and tolerability	—

Secondary

Measure	Time frame
Visual acuity	—

Countries

Egypt

Contacts

Public ContactMoataz Sallam

Lecturer at Faculty of Medicine Suez Canal University

moataz.sallam@med.suez.edu.eg+201111113588

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026